Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. [electronic resource]
Producer: 20140710Description: 495-501 p. digitalISSN:- 1432-0843
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- administration & dosage
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Bevacizumab
- Dose-Response Relationship, Drug
- Female
- Histone Deacetylase Inhibitors -- administration & dosage
- Humans
- Male
- Middle Aged
- Neoplasms -- blood supply
- Valproic Acid -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.